Stockreport

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF Ivonescimab Monotherapy Became First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab Monotherapy in a Phase III Randomized Clinical Trial in NSCLC, HARM [Read more]